Market Overview

Vetr Crowd Bearish On GW Pharma, But Upgrades To 3-Star Rating

Vetr Crowd Bearish On GW Pharma, But Upgrades To 3-Star Rating
Related GWPH
Pot Stocks & ETFs: This Week's Top News In The Cannabis Industry
Colorado Cannabis Sales Hit $1.49 Billion In 2017: Taxes Up To $247 Million, Medical Sales Down To $420 Million
ROTY Edition 1 Volume 72: Biotech Shines In January As We Manage Risk Appropriately (Seeking Alpha)

GW Pharmaceuticals PLC-ADR (NASDAQ: GWPH) has risen to $91.57 since its previous Vetr rating of 2.5 stars was issued two days ago. On Friday, the Vetr community upgraded their rating to three stars.

The British pharmaceutical company rallied on Tuesday on the release of positive data from their drug Epidiolex.

Related Link: GW Pharmaceuticals Surrenders Big Pre-Market Gains

Overall though, sentiment on Vetr is bearish. Less than 2 percent of Vetr users are holding it in their watch-lists, and 57 percent of the crowd's ratings are bearish. The Vetr crowd sees a price target of $89.66, compared to analyst projections $131.25.

See how Vetr's crowdsourced ratings can help you beat the market.

At time of writing, GW Pharma was up 1.64 percent at $93.07.

Latest Ratings for GWPH

Dec 2017Goldman SachsUpgradesNeutralBuy
Nov 2017Bank of AmericaMaintainsBuy
Oct 2017Leerink SwannMaintainsOutperform

View More Analyst Ratings for GWPH
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Downgrades Health Care Crowdsourcing Analyst Ratings Trading Ideas General


Related Articles (GWPH)

View Comments and Join the Discussion!